>>/216505/
Ещё он повышает активность Nrf2. 

> Relevance of anti-inflammatory and antioxidant activities of exemestane and synergism with sulforaphane for disease prevention
https://pmc.ncbi.nlm.nih.gov/articles/PMC3839725/
In conclusion, in addition to its potent mechanism-dependent inhibition of estrogen biosynthesis, exemestane has chemoprotective properties that have hitherto not been explicitly recognized. Exemestane should therefore be considered for use also in chemoprotection against mammary tumors that are not estrogen receptor-positive, and against a wide variety of nonmammary tumors (and possibly other chronic diseases) that are not estrogen-dependent but have oxidative stress, inflammation, and electrophile-damaging etiologies. The additional finding that exemestane shows powerful synergism with another widely consumed Nrf2-activator, sulforaphane, and a number of other phytochemicals, increases the attractiveness of this strategy. Our findings favor the view that use of exemestane with its broad range of actions, and its potential synergism with sulforaphane and other phytochemicals, could be a valuable chemoprotective strategy for reducing the risk of many malignancies and possibly other chronic diseases.

> Potential repositioning of exemestane as a neuroprotective agent for Parkinson's disease
https://sci-hub.ru/https://pubmed.ncbi.nlm.nih.gov/28770670/
The present study examined for the first time the effect of exemestane on the brain. Exemestane is highly lipophilic, and it distributes extensively into tissues, owing to its lipophilicity [59], suggesting that it can readily enter the brain. Our results demonstrated that exemestane activate the Nrf2 signalling pathway, induce gene expression of Nrf2-depensent enzyme genes, and suppress inflammatory responses. It also prevented microglial activation, dopaminergic neurodegeneration, and motor deficits in MPTP-treated mice. Therefore, exemestane repositioning for disease-modifying therapy for PD might be considered, in addition to its current usage in breast cancer.